Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter,randomized, open-label,phase 3 trial |
| |
| Authors: | Messoud Ashina MD PhD DMSc FEAN Stewart J. Tepper MD Uwe Reuter MD PhD Andrew M. Blumenfeld MD Susan Hutchinson MD Jing Xia PhD Rosa Miceli RN BSN CCRC Lawrence Severt MD PhD Michelle Finnegan MPH Joel M. Trugman MD |
| |
| Affiliation: | 1. Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;2. Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, New 3. Hampshire, USA;4. Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany;5. Headache Center of Southern California, Carlsbad, California, USA;6. Orange County Migraine and Headache Center, Irvine, California, USA;7. AbbVie, Madison, New Jersey, USA They were employees of AbbVie at the time of the study.;8. AbbVie, Madison, New Jersey, USA |
| |
| Abstract: | Objective To assess long-term safety, tolerability, and efficacy of once-daily oral atogepant 60 mg in adults with migraine. Background Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of episodic migraine. Methods A 52-week, multicenter, randomized, open-label trial of adults (18–80 years) with migraine. Lead-in trial completers or newly enrolled participants with 4–14 migraine days/month were enrolled and randomized (5:2) to atogepant 60 mg once daily or oral standard care (SC) migraine preventive medication. The primary objective was to evaluate the safety and tolerability of atogepant; safety assessments included treatment-emergent adverse events (TEAEs), clinical laboratory evaluations, vital signs, and Columbia-Suicide Severity Rating Scale scores. Efficacy assessments (atogepant only) included change from baseline in mean monthly migraine days (MMDs) and the proportion of participants with reductions from baseline of ≥50%, ≥75%, and 100% in MMDs. Results The trial included 744 participants randomized to atogepant 60 mg (n = 546) or SC (n = 198). The atogepant safety population was 88.2% female (n = 479/543) with a mean (standard deviation) age of 42.5 (12.0) years. TEAEs occurred in 67.0% (n = 364/543) of participants treated with atogepant 60 mg. The most commonly reported TEAEs (≥5%) were upper respiratory tract infection (10.3%; 56/543), constipation (7.2%; 39/543), nausea (6.3%; 34/543), and urinary tract infection (5.2%; 28/543). Serious TEAEs were reported in 4.4% (24/543) for atogepant. Mean (standard error) change in MMDs for atogepant was −3.8 (0.1) for weeks 1–4 and −5.2 (0.2) at weeks 49–52. Similarly, the proportion of participants with ≥50%, ≥75%, and 100% reductions in MMDs increased from 60.4% (310/513), 37.2% (191/513), and 20.7% (106/513) at weeks 1–4 to 84.2% (282/335), 69.9% (234/335), and 48.4% (162/335), at weeks 49–52. Conclusion Daily use of oral atogepant 60 mg for preventive treatment of migraine during this 1-year, open-label trial was safe, well tolerated, and efficacious. |
| |
| Keywords: | atogepant calcitonin gene–related peptide gepant migraine migraine preventive |
|
|
